Literature DB >> 31076172

Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.

Barry I Freedman1, Mitzie Spainhour2, Pamela J Hicks3, Jolyn Turner2, Julia Robertson4, Carl D Langefeld4, Mariana Murea2, Jasmin Divers4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31076172      PMCID： PMC9121021          DOI： 10.1053/j.ajkd.2019.03.414

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   11.072


× No keyword cloud information.
  10 in total

1.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

2.  Race, APOL1 Risk, and eGFR Decline in the General Population.

Authors:  Morgan E Grams; Casey M Rebholz; Yuan Chen; Andreea M Rawlings; Michelle M Estrella; Elizabeth Selvin; Lawrence J Appel; Adrienne Tin; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2016-03-10       Impact factor: 10.121

3.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

4.  Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.

Authors:  Girish N Nadkarni; Kinsuk Chauhan; Divya A Verghese; Chirag R Parikh; Ron Do; Carol R Horowitz; Erwin P Bottinger; Steven G Coca
Journal:  Kidney Int       Date:  2018-04-25       Impact factor: 10.612

5.  Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.

Authors:  Mariam Aghajan; Sheri L Booten; Magnus Althage; Christopher E Hart; Anette Ericsson; Ingela Maxvall; Joseph Ochaba; Angela Menschik-Lundin; Judith Hartleib; Steven Kuntz; Danielle Gattis; Christine Ahlström; Andrew T Watt; Jeffery A Engelhardt; Brett P Monia; Maria Chiara Magnone; Shuling Guo
Journal:  JCI Insight       Date:  2019-06-20

6.  A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.

Authors:  K V Lieberman; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-01       Impact factor: 10.121

7.  JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.

Authors:  Jasmin Divers; Marina Núñez; Kevin P High; Mariana Murea; Michael V Rocco; Lijun Ma; Donald W Bowden; Pamela J Hicks; Mitzie Spainhour; David A Ornelles; Steven B Kleiboeker; Kara Duncan; Carl D Langefeld; Jolyn Turner; Barry I Freedman
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

8.  The familial risk of end-stage renal disease in African Americans.

Authors:  B I Freedman; B J Spray; A B Tuttle; V M Buckalew
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

Review 9.  Hypertension-attributed nephropathy: what's in a name?

Authors:  Barry I Freedman; Arthur H Cohen
Journal:  Nat Rev Nephrol       Date:  2015-11-10       Impact factor: 28.314

10.  Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Authors:  Barry I Freedman; Carl D Langefeld; Jolyn Turner; Marina Núñez; Kevin P High; Mitzie Spainhour; Pamela J Hicks; Donald W Bowden; Amber M Reeves-Daniel; Mariana Murea; Michael V Rocco; Jasmin Divers
Journal:  Kidney Int       Date:  2012-06-13       Impact factor: 10.612
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.